Can a psoriasis drug stop transplant rejection?

NCT ID NCT04572815

Ongoing Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether the drug ustekinumab (Stelara) can prevent acute graft-versus-host disease (GVHD) in 116 adults receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. Ustekinumab aims to calm this immune response. Participants receive either the drug or a placebo, and researchers track how many develop GVHD over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ustekinumab (Stelara)
What this could lead to: If it works, this could offer a new way to prevent graft-versus-host disease, a serious complication after stem cell transplants.
What could go wrong: This is an early phase II trial with only 116 participants, so results may not apply to everyone. The drug may not reduce GVHD risk and could have side effects like infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease hematologic disorder hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm acute graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC AND LYMPHOCYTIC DISORDER HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center,

Duarte, California, 91010, United States
Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States
H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, 33612, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.